Ｂｉｓｐｈｏｓｐｈｏｎａｔｅ製剤およびＲａｌｏｘｉｆｅｎｅのコンプライアンスならびに有害事象調査（千葉県版ＤＥＭ）
スポンサーリンク
概要
- 論文の詳細を見る
To pharmacists,DEM (drug event monitoring) means the monitoring of events in patients taking certain drugs.We recently cooperated with pharmacies belonging to the Chiba Pharmaceutical Association to monitor events for bisphosphonates and raloxifene.These drugs were chosen because some of them have short usage records,as they have not been on the market for very long and have complicated dosing requirements.Pharmacies questioned patients who had been prescribed bisphosphonates such as etidronate disodium,alendronate sodium hydrate and sodium risedronate hydrate,or raloxifene hydrochloride with regard to compliance and post-dosing events.The proportions of patients who forgot to take their medication were significantly greater for alendronate and risedronate,which have complicated dosing regimens,than raloxifene,which has less complicated dosing regimens.As for adverse events,the percentages of patients who had gastrointestinal disorders were 15.8% for etidronate,7.9% for alendronate,5.7% for risedronate,and 6.1% for raloxifene.Further,incidence of gastrointestinal disorders was higher in patients taking stomach medications such as antacids,gastric acid-secretion inhibitors and gastric mucosa protectors together with alendronate or risedronate.In the present study,pharmacists'questioning of patients taking bisphosphonates or raloxifene clarified the status of compliance and occurrence rates of adverse events.Based on its results,we feel that more efforts should be made to collect patient information and counsel them on their medication in order to enhance the effectiveness and safety of drug therapy.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)